While Furiex Pharmaceuticals Inc. has hit its marks in two Phase studies of eluxadoline to treat diarrhea-predominant irritable bowel syndrome, it is hard to say how the response rates measure up to the only drug approved for the condition because FDA has changed its preferred endpoints.

Nevertheless, the data do look like they could support use of eluxadoline in IBS-D patients where GSK's Lotronex alosetron is not indicated: men and women with moderate disease.